Skip navigation



Cabume -

Cambridge Business Magazine

AMSBIO Introduce Purified Cancer Exosome Samples

AMSBIO has introduced a range of purified cancer exosome samples to help researchers study the role of exosomes in cancer development and metastasis. More »
22 June 2017

Invent Farma / neuraxpharm Group announces the acquisition of FB Health in Italy

First acquisition made by Invent Farma / neuraxpharm following the creation of the Group by funds advised by Apax Partners in August 2016 More »
22 June 2017

GHP International Life Science Awards 2017

Winner S-Curve Marketing Best-in-Class Life Sciences Commercial Business Consultancy - UK More »
21 June 2017

Cambridge start-ups invited to apply for sponsored place at major engineering exhibition

Ground-breaking Cambridge Network start-ups are urged to apply for a sponsored place in the innovation zone at the Advanced Engineering exhibition in Birmingham this November. More »
20 June 2017

Andy Harter, Cambridge Network Chair, awarded CBE

Dr Andy Harter FREng FIET FBCS has been awarded a CBE in the 2017 Queen’s Birthday Honours for notable and sustained contributions to engineering. More »
20 June 2017

LifeArc, previously MRC Technology, set to transform the medical research landscape

Investment will focus on new innovations in therapeutics for neurodegeneration, antibiotic resistance, cancer and respiratory diseases Newly rebranded UK medical research charity has also established two new funds to progress medical science More »
15 June 2017

Horizon Discovery’s RNA reference standards endorsed by Thermo Fisher Scientific’s White Paper

Horizon Discovery’s RNA reference standards endorsed by Thermo Fisher Scientific’s White Paper for use in cancer research testing. More »
15 June 2017

Post-Election Analysis

The snap Election had been widely expected (and intended) to deliver an increased majority to the Conservative Government and provide a mandate for its Brexit negotiating position. The result whereby the Conservatives lost their majority has triggered greater uncertainty. Here we analyse the implications of the result. More »
15 June 2017

Domainex Expands Partnership with Imperial College London to Reduce Heart Muscle Damage During Heart Attacks

Domainex Ltd. expands its partnership with Imperial College London, to discover novel therapies that reduce heart muscle damage during heart attacks. The aim is to discover a drug that inhibits the enzyme MAP4K4, which plays a key role in triggering cell death following a heart attack. More »
14 June 2017

Horizon Discovery Announces Progress of its Gene and Cell Therapy Platform for Contract Service and Therapeutic Applications

• Platform comprises Horizon’s viral, nuclease and transposon gene editing technologies for research and development • Three new contract wins contributing a value of more than $2 million in 2017 with potential for long-term alliance development More »
14 June 2017

<< Previous   Page 1 of 29   Next >>